Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOLD-100 plus FOLFOX with or without bevacizumab in advanced gastrointestinal solid tumors
2024-517500-11-00Phase 2Authorised
- Sponsor
- Bold Therapeutics
- Start
- Jul 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of BOLD-100 in colorectal cancer (CRC), gastric cancer (GC), pancreatic cancer (PC) and 4 more (2 arms), sponsored by Bold Therapeutics. Primary endpoints: Incidence and severity of adverse events, Incidence of serious adverse events and suspected unexpected serious adverse reactions and 5 more. Planned start Jul 2025; status: authorised.
02
Drugs
BOLD-100
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)pancreatic cancer (PC)cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on 2024-517500-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517500-11-00.